Sionna Therapeutics, Inc. (SION) Income Statement
SION 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSION revenue and net income
SION growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SION quarterly EPS vs estimates
Sionna Therapeutics beat the analyst EPS estimate in 3 of the last 7 quarters. Next report: November 4, 2026 (estimate $-0.62).
SION income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $647,000 | $668,000 | — | — |
| Gross profit | −$647,000 | −$668,000 | — | — |
| Research & development | $60.3M | $57.3M | $40.6M | $34.6M |
| Sales, general & admin | $28.7M | $13.3M | $9.7M | $6.8M |
| Total operating expenses | $88.3M | $69.9M | $50.3M | $41.4M |
| Operating income | −$89.0M | −$70.6M | −$50.3M | −$41.4M |
| Interest income | $13.3M | $8.2M | $2.8M | $1.1M |
| Income before taxes | −$75.3M | −$61.7M | −$47.3M | −$40.2M |
| Net income | −$75.3M | −$61.7M | −$47.3M | −$40.2M |
| EBITDA | −$74.6M | −$61.0M | −$46.7M | −$40.1M |
| EPS (diluted) | −$1.95 | −$3.38 | −$1.07 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $154,000 | $152,000 | $100,000 | $147,000 | — | — | — | $166,000 | — | — |
| Gross profit | — | −$154,000 | −$152,000 | −$100,000 | −$147,000 | — | — | — | −$166,000 | — | — |
| Research & development | $21.9M | $19.0M | $15.2M | $16.0M | $15.4M | $13.7M | $14.3M | $24.6M | $8.2M | $10.2M | $9.9M |
| Sales, general & admin | $10.6M | $10.8M | $9.9M | $7.2M | $6.5M | $5.6M | $3.9M | $4.2M | $2.7M | $2.6M | $2.7M |
| Total operating expenses | $32.5M | $29.4M | $23.5M | $23.8M | $21.8M | $19.7M | $18.1M | $28.0M | $11.1M | $13.1M | $12.6M |
| Operating income | −$32.5M | −$29.6M | −$23.6M | −$23.8M | −$21.9M | −$19.7M | −$18.1M | −$28.0M | −$11.3M | −$13.1M | −$12.6M |
| Interest income | $2.6M | $2.8M | $3.2M | $3.5M | $3.7M | $3.0M | $2.1M | $2.4M | $2.6M | $1.1M | $553,000 |
| Income before taxes | −$29.9M | −$26.8M | −$20.4M | −$20.3M | −$18.1M | −$16.5M | −$15.8M | −$25.4M | −$8.6M | −$11.8M | −$11.9M |
| Net income | −$29.9M | −$26.8M | −$20.4M | −$20.3M | −$18.1M | −$16.5M | −$15.8M | −$25.4M | −$8.6M | −$11.8M | −$11.9M |
| EBITDA | −$29.7M | −$26.6M | −$16.8M | −$20.2M | −$17.9M | −$16.1M | −$15.7M | −$25.3M | −$8.4M | −$11.5M | −$11.7M |
| EPS (diluted) | −$0.66 | −$0.60 | −$0.46 | −$0.46 | −$0.41 | −$0.62 | −$3.38 | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SION's financial statements (latest annual report filed March 2, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SION financial results
Sionna Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $75.3 million. Diluted earnings per share came to −$1.95.
See the SION stock overview for the latest quote and news, or the SION chart for price history and technical indicators.
SION income statement FAQ
Does Sionna Therapeutics have revenue?
Sionna Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Sionna Therapeutics profitable?
No. Sionna Therapeutics reported a net loss of $75.3 million in fiscal 2025.
How much does Sionna Therapeutics spend on research and development?
Sionna Therapeutics spent $60.3 million on research and development in fiscal 2025.
What are Sionna Therapeutics's earnings per share?
Sionna Therapeutics earned $-1.95 per diluted share in fiscal 2025, compared with $-3.38 a year earlier.
When will Sionna Therapeutics report its next earnings?
Sionna Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does Sionna Therapeutics's fiscal year end?
Sionna Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 2, 2026.